Presented at the 2023 Winter Clinical Hawaii Dermatology Conference January 13-18, 2023 Kohala Coast, Hawaii. What’s new and hot in alopecia areata management. It is an oral pill taken once daily, and has previous indications of ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis. Possible adverse effects of minoxidil include hypertrichosis, postural hypotension, and lower limb edema.įinally, an alopecia areata drug coming down the pipeline is etrasimod, a sphingosine 1-phosphate receptor modulator. Minoxidil is still a viable option for patients with alopecia areata, especially for those hesitant to start JAK inhibitors, or for pediatric patients. Dupilumab is an IL-4 and IL-13 antagonist currently approved to treat atopic dermatitis in children and adults. Mesinkovska cautioned clinicians to be aware of black box warnings of JAK inhibitors and to discuss adverse events with patients.ĭupilumab also shows promising potential for alopecia areata treatment. ![]() Current alopecia areata clinical trials include deuruxolitinibCTP 543, ritlecitinib, and delgotcitinib. Regarding JAK inhibitors, clinicians have a new JAK to choose from, baricitinib (Olumiant Eli Lily) for the treatment of alopecia areata in adults. Alopecia universalis is an uncommon form of alopecia areata (AA) involving hair loss over the entire scalp and body and is often difficult to treat. Mesinkovska stressed that she does not believe this should be a reason not to receive a COVID-19 vaccine or booster, but that clinicians should consider the effects and talk with their patients. Different regimens of pulse corticosteroid therapy have been described,1-5 with variable rates of effectiveness and adverse effects. Additionally, in a few patient examples, patients who previously had alopecia areata, but were stable or making progress, began to lose their hair again after the COVID-19 vaccine. To the Editor: The alopecia areata (AA) subtypes alopecia totalis (AT) and alopecia universalis (AU) are associated with poorer prognosis1 and are challenging to treat. In some examples, many of Mesinkovska’s patients experienced alopecia areata totalis after mild cases of COVID-19. Mesinkovska began by discussing the correlation between alopecia areata and COVID-19, as well as the COVID-19 vaccine and boosters. Mesinkovska’s session covered hot topics in alopecia areata management, including vaccines and viruses, JAK inhibitors, dupilumab, minoxidil, and what is coming down the pipeline. Mesinkovska is very involved in alopecia areata research, as she was the chief scientific officer of the National Alopecia Areata Foundation from 2015 to 2022 and is currently part of their clinical research advisory council. ![]() This review highlights mainly the pathomechanism and. Mesinkovska, MD, PhD, vice chair of clinical research in the department of dermatology at the University of California, Irvine, shares the latest pearls in alopecia areata management. Treatments include mainly corticosteroids, topical irritants, minoxidil, cytotoxic drugs and biologicals. In her session, “What’s New and Hot in Alopecia Areata Management,” Natasha A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |